信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

未开盘 12-20 16:08:10

35.200

-0.800

-2.22%

最高36.150	最低35.100	成交量828.98万
今开36.100	昨收36.000	日振幅2.92%
总市值576.58亿	流通市值576.58亿	总股本16.38亿
成交额2.94亿	换手率0.51%	流通股本16.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":35.2,"timestamp":1734682090015,"preClose":36,"halted":0,"volume":8289830,"delay":0,"floatShares":1638000000,"shares":1638000000,"eps":-0.70278084,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.8,"latestTime":"12-20 16:08:10","open":36.1,"high":36.15,"low":35.1,"amount":293722976,"amplitude":0.029167,"askPrice":35.3,"askSize":500,"bidPrice":35.2,"bidSize":77500,"shortable":3,"etf":0,"ttmEps":-0.8521702251006856,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"listingDate":1540915200000,"adjPreClose":36,"openAndCloseTimeList":[[1734658200000,1734667200000],[1734670800000,1734681600000]],"volumeRatio":1.4046862378583678,"impliedVol":0.4078,"impliedVolPercentile":0.0364,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK"},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2493249881","title":"信达生物(01801.HK)抑制剂达伯乐获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2493249881","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493249881?lang=zh_cn&edition=full","pubTime":"2024-12-22 20:52","pubTimestamp":1734871920,"startTime":"0","endTime":"0","summary":"信达生物(01801.HK) 公布，新一代ROS1酪氨酸激酶抑制剂“TKI”达伯乐的新药上市申请获中国国家药品监督管理局批准，用于经ROS1-TKI治疗后进展的ROS1阳性局部晚期或转移性非小细胞肺癌成人患者的治疗。达伯乐是公司第13款商业化产品。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-20 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190319115557208_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190319115557208_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405740/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1589","LU1969619763.USD","LU2488822045.USD","LU2328871848.SGD","BK1583","01801"],"gpt_icon":0},{"id":"2493245403","title":"南向资金12月20日持有信达生物市值153.95亿港元，持股比例占26.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493245403","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493245403?lang=zh_cn&edition=full","pubTime":"2024-12-21 07:09","pubTimestamp":1734736187,"startTime":"0","endTime":"0","summary":"12月21日，Choice数据显示，南向资金截至12月20日持有信达生物4.37亿股，持股市值153.95亿港元，较上个交易日减少3.43亿港元，持股数量占发行股的26.69%。截至20日收盘，信达生物当日下跌2.22%，收盘价报35.2港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221071443a1fefc0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221071443a1fefc0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","LU2328871848.SGD","LU1969619763.USD","BK1583","BK1589","01801"],"gpt_icon":0},{"id":"2493470395","title":"信达生物宣布ROS1抑制剂达伯乐®（己二酸他雷替尼胶囊）获国家药品监督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2493470395","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493470395?lang=zh_cn&edition=full","pubTime":"2024-12-20 20:08","pubTimestamp":1734696480,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年12月20日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司宣布，新一代ROS1酪氨酸激酶抑制剂达伯乐的新药上市申请获中国国家药品监督管理局批准上市，用于经ROS1-TKI治疗后进展的ROS1阳性局部晚期或转移性非小细胞肺癌成人患者的治疗。截至目前，信达生物患者援助项目已惠及17余万普通患者，药物捐赠总价值34亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4584619_ZH84619_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1969619763.USD","IVBIY","NUVB","GRO","ODD","01801","BK1589","BK1161","BK1583","BK4139","BK4183","BK4007","LU2488822045.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2492411220","title":"信达生物新药己二酸他雷替尼胶囊获NMPA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2492411220","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492411220?lang=zh_cn&edition=full","pubTime":"2024-12-20 19:46","pubTimestamp":1734695177,"startTime":"0","endTime":"0","summary":"财中社12月20日电信达生物（01801）发布公告，宣布其新一代ROS1抑制剂达伯乐?（己二酸他雷替尼胶囊）获得中国国家药品监督管理局（NMPA）批准上市，适用于经ROS1-TKI治疗后进展的ROS1阳性局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。该产品是公司第13款商业化产品，旨在满足ROS1突变肺癌患者的治疗需求，进一步增强公司在肿瘤精准治疗领域的竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412203274667342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU2328871848.SGD","LU2488822045.USD","BK1583","BK1161","01801","BK1589"],"gpt_icon":0},{"id":"2492416324","title":"信达生物(01801)：ROS1抑制剂达伯乐® (己二酸他雷替尼胶囊)获国家药品监督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2492416324","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492416324?lang=zh_cn&edition=full","pubTime":"2024-12-20 19:13","pubTimestamp":1734693219,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 公布，新一代ROS1酪氨酸激酶抑制剂达伯乐 的新药上市申请获中国国家药品监督管理局批准上市，用于经ROS1-TKI治疗后进展的ROS1阳性局部晚期或转移性非小细胞肺癌成人患者的治疗。达伯乐是公司第13款商业化产品，这一创新精准疗法将惠及ROS1突变的肺癌患者，并进一步加强公司在肿瘤精准治疗领域的品牌和产品组合优势。临床结果提示，特别在 ROS1抑制剂经治的患者中，达伯乐充分展现了对这一未满足需求的治疗潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物(01801)：ROS1抑制剂达伯乐® (己二酸他雷替尼胶囊)获国家药品监督管理局批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","BK1583","LU2488822045.USD","BK1161","01801","LU1969619763.USD","BK1589"],"gpt_icon":0},{"id":"2492452543","title":"美银证券：重申信达生物(01801)及翰森制药(03692)“买入”评级 目标价均上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2492452543","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492452543?lang=zh_cn&edition=full","pubTime":"2024-12-20 11:47","pubTimestamp":1734666421,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研究报告称，信达生物(01801)日前与礼来(LLY.US)就后者的非共价(可逆)BTK抑制剂“捷帕力”达成中国大陆商业化协议，将该产品的销售预测计算在内后，相应将公司2025及2026年收入预测分别上调1.9%及3.4%，目标价从54.1港元上调至56.4港元，重申“买入”评级。报告中称，翰森制药(03692)早前与默沙东订立协议，授出临床前口服小分子GLP-1受体激动剂HS-10535的开发、生产及商业化全球独家许可。美银将其将2025年收入及每股盈利预测分别上调6.9%及19.2%，目标价从23.9港元上调至24港元，重申“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","161027","03692"],"gpt_icon":0},{"id":"2492941582","title":"创新药概念多数上扬 圣诺医药(02257)涨11.56% 机构指医药创新是医药增长的核心动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2492941582","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492941582?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:55","pubTimestamp":1734486946,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念多数上扬，圣诺医药 涨11.56%，百奥赛图涨9.68%，歌礼制药涨7.98%，绿竹生物涨4.73%，再鼎医药涨4.41%，康诺亚涨1.34%，中国生物制药涨0.95%，信达生物涨0.69%银河证券表示，1）医药创新是医药增长的核心动力。对于医药板块， 在“医保+商保”模式不断推进、政策支持等因素驱动下，行业规模有望进一步扩大。“医保+商保”模式打开健康险空间，创新药发展空间更大。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949850","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK1583","LU1969619763.USD","BK1587","159938","01177","02257","BK1161","LU2328871848.SGD","01801","02162","BK1589","09688","02315","BK1191","06978","BK1521","BK1574","09939","01672","LU2488822045.USD","BK1588","BK1515","02480"],"gpt_icon":0},{"id":"2492498545","title":"【券商聚焦】国证国际：创新药企和医疗器械公司有望通过出海不断打开市场天花板","url":"https://stock-news.laohu8.com/highlight/detail?id=2492498545","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492498545?lang=zh_cn&edition=full","pubTime":"2024-12-17 14:20","pubTimestamp":1734416402,"startTime":"0","endTime":"0","summary":"对于医药板块， 在“医保+商保”模式不断推进、政策支持等因素驱动下，行业规模有望进一步扩大。由于中美定价差异大，企业可通过license out不断打开市场天花板。“医保+商保”模式打开健康险空间，创新药发展空间更大。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949796","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","159992","BK1222","09996","BK1587","BK1191","159883","01801","BK1521","01177","BK1583","BK1515","BK1181","BK1100","06978","LU2488822045.USD","02162","09997","BK1161","LU2328871848.SGD","BK1574","BK1589","06880"],"gpt_icon":0},{"id":"2492674842","title":"21健讯Daily｜四部门印发《职业病分类和目录》；信达生物与礼来制药深化肿瘤领域合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2492674842","media":"21综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492674842?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:15","pubTimestamp":1734398100,"startTime":"0","endTime":"0","summary":"圣湘生物此次获证，有助于提升其在传染病检测领域的竞争力。行业大事信达生物与礼来制药深化肿瘤领域合作12月16日，信达生物和礼来共同宣布，双方就礼来的非共价（可逆）布鲁顿氏酪氨酸激酶抑制剂匹妥布替尼在中国大陆的权益达成合作协议。本次计提将影响2024年度公司合并报表归属于上市公司股东的净利润减少7196.27万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093531a1f46d2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093531a1f46d2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","01801","LU2488822045.USD","BK1574","LU1969619763.USD","BK1161","LU2328871848.SGD","BK1589","BK1191","BK1583"],"gpt_icon":0},{"id":"2491932106","title":"金十数据整理：每日美股市场要闻速递（12月16日 周一）","url":"https://stock-news.laohu8.com/highlight/detail?id=2491932106","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491932106?lang=zh_cn&edition=full","pubTime":"2024-12-16 21:05","pubTimestamp":1734354358,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["VWAGY","LU2430703251.USD","LU2461242641.AUD","BK4575","LU0234572021.USD","LU1989771016.USD","LU0114720955.EUR","IE0009355771.USD","SNY","LU1868836591.USD","03160","BK4532","IE00B3S45H60.SGD","LU0011850046.USD","LU2237443978.SGD","VLKAY","IE00BJJMRY28.SGD","LU0494093205.USD","LU0077335932.USD","LU1585245621.USD","LU2237443895.HKD","MACW.SI","LU1974910355.USD","LU2023250843.SGD","LU0784383803.USD","LU1823568750.SGD","LU0314106906.USD","LU0256863902.USD","HK0000306685.HKD","LU1778281490.HKD","SG9999014542.SGD","GILD","SHEL","IE0004086264.USD","IE0002141913.USD","LU0965509010.AUD","SFTBY","RDSA.UK","01801","LU0949170426.SGD","RDS.A","RDS.B","AAPL","LLY","0O59.UK","LU1791710400.SGD","LU1116320901.HKD","NVO","LU0385154629.USD","IE00B19Z8X17.USD"],"gpt_icon":0},{"id":"2491865399","title":"信达生物(01801)下跌3.21%，报36.2元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491865399","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491865399?lang=zh_cn&edition=full","pubTime":"2024-12-16 15:25","pubTimestamp":1734333924,"startTime":"0","endTime":"0","summary":"12月16日，信达生物(01801)盘中下跌3.21%，截至15:25，报36.2元/股，成交3.0亿元。信达生物主要致力于研发、生产和销售针对肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，已成功上市10个产品，同时有4个品种在审评中，4个新药分子进入III期或关键性临床研究，另有18个新药品种已入临床研究。至2023年10月，其患者援助项目已惠及17余万患者，药物捐赠总价值达34亿人民币。截至2024年中报，信达生物营业总收入39.52亿元、净利润-3.93亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/16152546415436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","LU2328871848.SGD","01801","BK1161","LU2488822045.USD","BK1589","LU1969619763.USD"],"gpt_icon":0},{"id":"2491166873","title":"上市两个月，礼来将匹妥布替尼片“外包”给信达生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2491166873","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491166873?lang=zh_cn&edition=full","pubTime":"2024-12-16 15:17","pubTimestamp":1734333428,"startTime":"0","endTime":"0","summary":"刚上市不到两个月，礼来就将商业化权益“外包”给信达生物，是出于什么考量？根据礼来10月公众号发文，匹妥布替尼是全球首个获批用于既往接受过共价BTK抑制剂治疗的套细胞淋巴瘤患者的BTK抑制剂。据中新经纬检索，目前除了匹妥布替尼，中国市场上还没有其他上市的非共价BTK抑制剂，礼来为什么会把这款新药销售权益交给信达生物？据礼来，该公司与信达生物拥有长期的战略合作关系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216180214a1f2b70e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216180214a1f2b70e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2360106947.USD","LU0417517546.SGD","LU0456855351.SGD","LU1291159041.SGD","LU2461242641.AUD","LU0203201768.USD","LU1064131342.USD","LLY","BK4585","LU1868836914.USD","SGXZ81514606.USD","LU0106261372.USD","LU0238689110.USD","LU0354030438.USD","LU0471298777.SGD","LU2361044865.SGD","SG9999018857.SGD","LU2211815571.USD","SGXZ31699556.SGD","BK4599","LU2602419157.SGD","IE00BK4W5L77.USD","SG9999013999.USD","IE00BJJMRZ35.SGD","IE0004445239.USD","LU0061475181.USD","LU2237443465.HKD","LU1069344957.HKD","LU1712237335.SGD","LU2265009873.SGD","LU1989771016.USD","SG9999015952.SGD","IE00BJLML261.HKD","BK4581","LU0385154629.USD","SGXZ51526630.SGD","LU0122379950.USD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU1623119135.USD","LU0058720904.USD","LU2237443895.HKD","LU0943347566.SGD","LU0689472784.USD","LU2237438978.USD","LU2361044949.HKD","01801","LU1127390331.HKD","IE00B4R5TH58.HKD","LU2106854487.HKD","LU0079474960.USD"],"gpt_icon":1},{"id":"2491682990","title":"信达生物(01801.HK)与礼来(LLY.US)达成“捷帕力”中国大陆商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2491682990","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491682990?lang=zh_cn&edition=full","pubTime":"2024-12-16 10:04","pubTimestamp":1734314640,"startTime":"0","endTime":"0","summary":"信达生物与礼来宣布，就礼来非共价(可逆)BTK抑制剂“捷帕力”在中国大陆的权益达成合作协议，将由信达生物负责捷帕力的进口、销售、推广和分销工作，而礼来则负责捷帕力的研发和上市后医学事务相关工作。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220906114108815_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220906114108815_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1404230&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2488822045.USD","BK1161","LU2328871848.SGD","LU1969619763.USD","BK1583","BK1589","01801"],"gpt_icon":0},{"id":"2491863496","title":"礼来(LLY)与信达生物达成捷帕力（匹妥布替尼片）中国大陆商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2491863496","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491863496?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:34","pubTimestamp":1734312896,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据媒体报道，礼来(LLY)12月16日和信达生物制药集团共同宣布就礼来非共价（可逆）BTK抑制剂捷帕力（匹妥布替尼100毫克和50毫克片剂）在中国大陆的权益达成以下合作协议：信达生物将负责捷帕力的进口、销售、推广和分销工作；礼来将负责捷帕力的研发和上市后医学事务相关工作。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"283235","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK4599","IE0009355771.USD","SG9999018857.SGD","LU0097036916.USD","SG9999014906.USD","LU2237443978.SGD","LU2491049909.HKD","LU2063271972.USD","LU2265009873.SGD","LU2491050154.USD","LU0256863811.USD","LU1804176565.USD","IE00BJT1NW94.SGD","LU1035775433.USD","LU2264538146.SGD","LU1868837300.USD","IE00B1BXHZ80.USD","IE00BFTCPJ56.SGD","LU0471298694.HKD","LU1023059063.AUD","LU2237443465.HKD","BK4533","LU0689472784.USD","SGXZ99366536.SGD","LU0079474960.USD","LU2089984988.USD","LU2237438978.USD","LU0061475181.USD","LU0058720904.USD","LU0289739699.SGD","SG9999017495.SGD","LU0256863902.USD","LU1057294990.SGD","01801","BK1589","LU0820561818.USD","LU1712237335.SGD","LU2237443622.USD","LU1291159041.SGD","LU0006306889.USD","LU0122379950.USD","LU0640476718.USD","BK4581","LLY","IE00BK4W5M84.HKD","BK4585","SGXZ81514606.USD","LU1868836914.USD","LU0238689110.USD"],"gpt_icon":0},{"id":"2491686728","title":"信达生物(01801)与礼来就BTK抑制剂癌症新药达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2491686728","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491686728?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:24","pubTimestamp":1734312274,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月16日，信达生物和礼来共同宣布，就礼来非共价（可逆）BTK抑制剂捷帕力在中国内地的权益达成以下合作协议：信达生物将负责捷帕力的进口、销售、推广和分销工作；礼来将负责捷帕力的研发和上市后医学事务相关工作。匹妥布替尼于2023年1月获得美国FDA批准，并于2024年10月获得中国NMPA批准，单药适用于既往接受过至少两种系统性治疗的复发或难治性套细胞淋巴瘤成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0689472784.USD","BK4588","LU0106261372.USD","SG9999018857.SGD","LU1868836591.USD","BK4599","SG9999014898.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU2491049909.HKD","LU1969619763.USD","LU0256863902.USD","LU0079474960.USD","SGXZ57979304.SGD","LU0882574139.USD","LU0198837287.USD","LU0385154629.USD","LU2237443382.USD","LU2237443622.USD","IE00BK4W5L77.USD","SG9999001176.SGD","LU1868836914.USD","LLY","LU1061106388.HKD","LU2491050154.USD","LU2602419157.SGD","LU0354030511.USD","LU2237438978.USD","LU2265009873.SGD","LU1988902786.USD","BK4585","LU0820561818.USD","LU1989771016.USD","SGXZ81514606.USD","LU2237443549.SGD","SGXZ99366536.SGD","LU2361044865.SGD","LU0471298694.HKD","LU1267930730.SGD","LU0006306889.USD","LU1974910355.USD","SGXZ31699556.SGD","LU0820561909.HKD","LU0471298777.SGD","SG9999013999.USD","LU2063271972.USD","LU2237443465.HKD","01801","GB00BDT5M118.USD","LU0289739699.SGD"],"gpt_icon":1},{"id":"2491201683","title":"礼来与信达生物达成捷帕力（匹妥布替尼片）中国大陆商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2491201683","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491201683?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:11","pubTimestamp":1734311489,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1712237335.SGD","IE00B1BXHZ80.USD","LU0354030438.USD","LU2328871848.SGD","GB00BDT5M118.USD","IE0002141913.USD","LU0058720904.USD","BK4588","LU0385154629.USD","LU1868836591.USD","LU0471298777.SGD","LU1064131342.USD","LU0122379950.USD","IE00B2B36J28.USD","LU2237443465.HKD","LU2237443895.HKD","LU2488822045.USD","LU1974910355.USD","LU0061475181.USD","BK1574","LU2360106947.USD","01801","LU0456855351.SGD","LU0320765059.SGD","IE00BFTCPJ56.SGD","LU0820561818.USD","LU0097036916.USD","SGXZ99366536.SGD","IE0004445239.USD","LU0079474960.USD","BK4599","LU0708995401.HKD","BK4534","LU2237443382.USD","SGXZ51526630.SGD","LU1989771016.USD","IE00B4R5TH58.HKD","IE0009355771.USD","01477","LU0471298694.HKD","SG9999015978.USD","LU0943347566.SGD","IE00BK4W5M84.HKD","SG9999014880.SGD","LU2106854487.HKD","LU0882574139.USD","LLY","LU1127390331.HKD","LU2237443622.USD","LU1280957306.USD"],"gpt_icon":0},{"id":"2491729653","title":"信达生物与礼来制药深化肿瘤领域合作，达成捷帕力®（匹妥布替尼片）中国大陆商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2491729653","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491729653?lang=zh_cn&edition=full","pubTime":"2024-12-16 07:55","pubTimestamp":1734306900,"startTime":"0","endTime":"0","summary":"根据协议，信达生物拥有捷帕力在中国大陆的进口、销售、推广和分销权利，礼来将负责该产品在中国大陆的持续研发和上市后医学事务相关工作。此次合作将充分利用信达生物在血液肿瘤领域丰富的商业化经验及礼来医学团队在血液肿瘤领域丰富的开发经验和科学洞见。双方将强强联手，致力于造福更多中国大陆癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4580201_ZH80201_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0882574055.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU0672654240.SGD","LU1868836757.USD","LU1064131342.USD","SG9999001176.SGD","SG9999015945.SGD","SG9999018857.SGD","LU0097036916.USD","LU2237443978.SGD","IE00BJLML261.HKD","LU2488822045.USD","LU0109391861.USD","LU1917777945.USD","LU2063271972.USD","LU2361044865.SGD","LU1035775433.USD","LU1988902786.USD","LU0203202063.USD","IE00B1BXHZ80.USD","LU0471298694.HKD","LU2361044949.HKD","BK4533","LU0114720955.EUR","LU2360106947.USD","SG9999015952.SGD","LU2237438978.USD","LU0061475181.USD","LU0058720904.USD","LU0823416689.USD","BK1583","SG9999017495.SGD","LU0256863902.USD","01801","LU2237443549.SGD","LU2361045086.USD","LU0094547139.USD","LU0943347566.SGD","SG9999015986.USD","LU0006306889.USD","LU0471298777.SGD","SG9999014898.SGD","LU1127390331.HKD","LLY","IVBIY","SGXZ81514606.USD","BK4588","LU2602419157.SGD","LU0238689110.USD"],"gpt_icon":1},{"id":"2490878729","title":"【券商聚焦】中信建投升信达生物(01801)目标价至71.92港元 指其在肿瘤赛道布局已初具规模","url":"https://stock-news.laohu8.com/highlight/detail?id=2490878729","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490878729?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:05","pubTimestamp":1733987143,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投发研报指，信达生物 在最新的ESMOAsia大会上更新了IBI343在胰腺癌上的数据，43例二线及以上胰腺癌患者的ORR为32.6%，cORR为23.6%，cDCR为81.4%，mPFS为5.3个月，mPFS超出现有三线疗法的mPFS，也超过现有二线疗法的mPFS。该行预计信达生物2024-2026年收入为82.50亿元、107.32亿元和153.83亿元，采用DCF估值，公司合理市值为1167亿港元，上调目标价至71.92港元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjEwODMyZjRkNWI4NjVjNzFhNGY4NWE0ZDExNzMxMDU0NzE5MDIz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjEwODMyZjRkNWI4NjVjNzFhNGY4NWE0ZDExNzMxMDU0NzE5MDIz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"gpt_icon":0},{"id":"2490077551","title":"信达生物12月10日获南向资金加仓119.48万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490077551","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490077551?lang=zh_cn&edition=full","pubTime":"2024-12-11 09:30","pubTimestamp":1733880617,"startTime":"0","endTime":"0","summary":"12月10日, 南向资金增持信达生物119.48万股。截止当日收盘，港股通共持有信达生物43575.21万股，占流通股26.60%。信达生物近5个交易日上涨0.39%，港股通累计增持1178.66万股；近20个交易日上涨1.06%，港股通累计增持2775.83万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211093151a1e4be63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211093151a1e4be63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2488822045.USD","01801","BK1583","BK1589","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2490855775","title":"信达生物(1801.HK)：CLDN18.2ADC胰腺癌数据优秀 疗效与安全性兼顾","url":"https://stock-news.laohu8.com/highlight/detail?id=2490855775","media":"中信建投证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490855775?lang=zh_cn&edition=full","pubTime":"2024-12-11 00:00","pubTimestamp":1733846400,"startTime":"0","endTime":"0","summary":"事件12 月9 日，公司在2024 年欧洲肿瘤内科学会亚洲年会大会上口头报道了IBI343治疗晚期胰腺导管腺癌临床I 期数据更新。点评IBI343 在胰腺癌上展现突出疗效与良好安全性数据在2024 年ESMO Asia 大会上， 信达生物公布了IBI343在胰腺癌上的疗效数据，该I 期临床共计入组4 3例CLDN18.2 阳性胰腺癌患者，所有患者均接受3mg/kg Q3W 的治疗。我们认为信达的IBI343 在CLDN18.2 阳性的胰腺癌患者中展现出了突出的疗效，患者mPFS达到5.3 个月，超出现有疗法水平，未来可期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211201010a1e61f9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211201010a1e61f9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","LU2488822045.USD","BK1583","LU2328871848.SGD","LU1969619763.USD","BK1161","BK1589"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0588},{"period":"1month","weight":-0.0928},{"period":"3month","weight":-0.1737},{"period":"6month","weight":-0.0435},{"period":"1year","weight":-0.1145},{"period":"ytd","weight":-0.1766}],"compareEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0801},{"period":"6month","weight":0.0939},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1568}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销，以及提供咨询及研发服务。该公司的主要产品为达伯舒（信迪利单抗注射液），用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303，用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305，用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌（NSCLC）。利妥昔单抗生物类似药IBI-301，用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.049204},{"month":2,"riseRate":0.666667,"avgChangeRate":0.101831},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050735},{"month":4,"riseRate":0.666667,"avgChangeRate":0.022046},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006538},{"month":6,"riseRate":0.666667,"avgChangeRate":0.118103},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.029935},{"month":8,"riseRate":0.833333,"avgChangeRate":0.002206},{"month":9,"riseRate":0.666667,"avgChangeRate":0.03832},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.010418},{"month":11,"riseRate":0.571429,"avgChangeRate":0.078824},{"month":12,"riseRate":0.428571,"avgChangeRate":0.049369}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}